IRIS
PACINI, FURIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.937
EU - Europa 6.083
AS - Asia 871
AF - Africa 13
OC - Oceania 12
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 8
Totale 13.933
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.926
GB - Regno Unito 2.179
IE - Irlanda 958
IT - Italia 732
CN - Cina 613
UA - Ucraina 563
SE - Svezia 518
RU - Federazione Russa 333
DE - Germania 276
FR - Francia 276
FI - Finlandia 144
SG - Singapore 126
VN - Vietnam 56
BE - Belgio 29
TR - Turchia 25
ES - Italia 19
IN - India 18
NL - Olanda 15
PL - Polonia 10
CA - Canada 8
EU - Europa 8
IR - Iran 8
AU - Australia 7
HK - Hong Kong 7
CI - Costa d'Avorio 6
CZ - Repubblica Ceca 6
AT - Austria 5
NZ - Nuova Zelanda 5
CH - Svizzera 4
CL - Cile 4
RO - Romania 4
BR - Brasile 3
CU - Cuba 2
CY - Cipro 2
EE - Estonia 2
EG - Egitto 2
HU - Ungheria 2
IL - Israele 2
IQ - Iraq 2
KR - Corea 2
MA - Marocco 2
MY - Malesia 2
ZA - Sudafrica 2
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CO - Colombia 1
DK - Danimarca 1
GE - Georgia 1
GR - Grecia 1
IM - Isola di Man 1
IS - Islanda 1
JO - Giordania 1
JP - Giappone 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MT - Malta 1
MX - Messico 1
PK - Pakistan 1
SN - Senegal 1
TH - Thailandia 1
Totale 13.933
Salva come PNG Salva come JPEG
Città #
Southend 2.062
Fairfield 1.263
Dublin 939
Chandler 598
Woodbridge 594
Ashburn 582
Wilmington 478
Seattle 472
Jacksonville 450
Houston 446
Cambridge 418
Siena 306
Ann Arbor 292
Princeton 154
Nanjing 152
Beijing 127
Boardman 80
Singapore 79
San Diego 66
Helsinki 65
Dong Ket 56
Nanchang 55
Moscow 48
San Mateo 44
Saint Petersburg 40
Düsseldorf 35
London 30
Florence 29
Shenyang 29
Brussels 27
Kunming 27
Jiaxing 26
Lancaster 26
Shanghai 26
Tianjin 26
Hebei 24
Izmir 21
Milan 20
New York 20
Dearborn 19
Prato 19
Changsha 18
Norwalk 18
Redwood City 18
Washington 18
Jinan 17
Málaga 16
Zhengzhou 15
Renton 13
Ningbo 12
Rome 12
Venezia 12
Guangzhou 10
Los Angeles 9
Menlo Park 9
Phoenix 9
Naples 8
Arezzo 7
Chicago 7
Hangzhou 7
Palermo 7
San Francisco 7
Saronno 7
Abidjan 6
Codogno 6
Falls Church 6
Munich 6
Salerno 6
Taizhou 6
Bari 5
Brno 5
Dallas 5
Edinburgh 5
Melbourne 5
Santa Clara 5
Toronto 5
Vienna 5
Frankfurt am Main 4
Hefei 4
Hong Kong 4
Lanzhou 4
Modena 4
Oak Park 4
Teverola 4
Zanjan 4
Amsterdam 3
Auckland 3
Belvedere Marittimo 3
Belvedere di Spinello 3
Bonndorf 3
Brescia 3
Cincinnati 3
Delhi 3
Falkenstein 3
Fremont 3
Fuzhou 3
Gliwice 3
Lamezia Terme 3
Lausanne 3
Monteroni D'arbia 3
Totale 10.679
Salva come PNG Salva come JPEG
Nome #
null 398
Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor 233
Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer 231
Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias 208
Obesity Does Not Modify the Risk of Differentiated Thyroid Cancer in a Cytological Series of Thyroid Nodules 206
Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes 197
Reference range of serum calcitonin in pediatric population 195
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer 192
Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients 187
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. 184
Weight loss associated with bariatric surgery does not restore short telomere length of severe obese patients after 1 year 179
MicroRNA expression profile of thyroid nodules in fine-needle aspiration cytology: a confirmatory series 173
Lack of Mutations of the Telomerase RNA Component in Familial Papillary Thyroid Cancer with Short Telomeres. 171
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 171
Alterations of the FSH and LH receptor genes and evaluation of sperm ultrastructure in men with idiopathic hypergonadotropic hypogonadism. 170
Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients 170
Acute exogenous TSH administration stimulates leptin secretion in vivo. 166
Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone 165
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer 164
Management of papillary thyroid microcarcinoma: primum non nocere! 163
Diagnostic, therapeutic and healthcare management protocols in parathyroid surgery: II Consensus Conference of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB) 163
Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients 162
Approach to and treatment of differentiated thyroid carcinoma 162
DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients 161
Circulating miRNA95 and miRNA190 Are Sensitive Markers for the Differential Diagnosis of Thyroid Nodules in a Caucasian Population. 152
Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer 151
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up 150
Definition and management of radioactive iodine-refractory differentiated thyroid cancer 148
Telomere Abnormalities and Chromosome Fragility in Patients Affected by Familial Papillary Thyroid Cancer. 147
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment 147
Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. 146
Lack of germline A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) gene in familial papillary thyroid cancer. 145
Ernest L. Mazzaferri, MD, MACP (1936-2013) 144
Changing natural history of differentiated thyroid cancer. 143
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 142
Variants in MCT10 protein do not affect FT3 levels in athyreotic patients 142
Medullary thyroid carcinoma. 140
Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer 139
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients 139
Management of thyroid nodules: a clinicopathological, evidence-based approach 138
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 138
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update 138
Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: results from a multicenter, international, randomized, placebo-controlled, dose-selection study 137
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 136
Screening of thyroid nodules by serum calcitonin measurements: why not? 133
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 133
Reply to letter: Post-surgical thyroid ablation in intermediate risk-differentiated thyroid cancer patients 131
Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients 131
Mutations and polymorphism of LH and FSH receptors and sperm quality in men with hypergonadotropic hypogonadism without obvious testicular noxa 131
H. pylori (hp) infection and autoimmune diseases (ad): prevalence of infection in patients with Hashimoto's thyroiditis (ht) and allignement of thyroid hormones (th) with H. pylori proteins. 128
Observation for newly diagnosed micro-papillary thyroid cancer: is now the time? 128
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. 128
Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer. 126
null 126
Management of differentiated thyroid cancer of the follicular epithelium. 124
Post-thyroidectomy chronic asthenia: self-deception or disease? 124
Long-Term Clinical Outcome in Familial and Sporadic Papillary Thyroid Carcinoma 124
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma 123
Prevalence of parietal cell antibodies in a large cohort of patients with autoimmune thyroiditis. 123
Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions 121
The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels 121
Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? 121
Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology 121
Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. 120
Telomeres and thyroid cancer. 119
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. 119
Genetic heterogeneity of HER2 amplification and telomere shortening in papillary thyroid carcinoma 115
Effects of Acute Recombinant Human TSH on Serum Ghrelin Levels 113
Serum Ghrelin As a Marker of Atrophic Body Gastritis in Patients With Parietal Cell Antibodies 112
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial 112
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study 111
Rare diseases in clinical endocrinology: a taxonomic classification system 111
Medullary thyroid cancer: management guidelines of the American Thyroid Association. 111
Targeted therapy in refractory thyroid cancer: current achievements and limitations. 110
How Far Should We Go in the Search and Treatment of Recurrent or Persistent Lymph Node Metastases during Follow-Up of Thyroid Cancer Patients? 110
Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. 109
Management of advanced medullary thyroid cancer 109
Molecular signature of indeterminate thyroid lesions: Current methods to improve fine needle aspiration cytology (FNAC) diagnosis 109
The low utility of pretherapy scans in thyroid cancer patients. 108
Multinodular goiter of unusual shape and location 106
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. 105
HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series 105
IFNγ-Inducible Chemokines Decrease upon Selenomethionine Supplementation in Women with Euthyroid Autoimmune Thyroiditis: Comparison between Two Doses of Selenomethionine (80 or 160 μg) versus Placebo 103
Thyroid microcarcinoma. 102
Best practice & research clinical endocrinology & metabolism. Thyroid nodules and cancer. Preface 101
New insight in the follow-up strategies of differentiated thyroid cancer 101
Validation of American Thyroid Association Ultrasound Risk-Adapted Approach for Repeating Cytology in Benign Thyroid Nodules 100
Calcitonin Levels in Thyroid Disease Are Not Affected by Autoimmune Thyroiditis or Differentiated Thyroid Carcinoma 99
Down modulation of IG20/MADD expression or phosphorylation renders TRAIL resistant thyroid cancer cells susceptible to TRAIL treatment. 98
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. 98
Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. 96
null 94
Extracellular superoxide dismutase induces mouse embryonic fibroblast proliferative burst, growth arrest, immortalization, and consequent in vivo tumorigenesis 92
RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration 92
Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. 90
The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. 82
Response Letter to the Editor from Edmundo Avila-Hipolito: "Long-term effects of radioiodine in toxic multinodular goitre: thyroid volume, function and autoimmunity" 76
null 75
A case of papillary thyroid cancer without aggressive histological features with nodal metastases detected during follow-up in a younger patients 62
null 60
Totale 13.565
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.681
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.681
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.577 0 0 208 503 211 217 293 400 289 231 62 163
2020/20212.358 84 232 75 221 172 293 134 381 181 237 161 187
2021/20221.351 133 196 79 105 74 60 64 44 85 147 149 215
2022/20232.035 117 180 267 288 202 396 44 178 223 35 76 29
2023/20241.304 70 34 110 43 52 363 476 22 6 19 16 93
2024/2025451 62 149 240 0 0 0 0 0 0 0 0 0
Totale 14.125